Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China

Overview of attention for article published in Frontiers in oncology, December 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 25,161 followers.

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China https://t.co/7zBqANMKg9 https://t.co/hlMy3rxwb3

13 Dec 2022

Reply Repost Favourite

New research: Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China: Objective To evaluate the economics of sugemalimab plus chemotherapy in the first-line treatment of metastatic… https://t.co/

13 Dec 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.